Premium
Medicines Regulation and Health Technology Assessment
Author(s) -
Breckenridge A,
Woods K,
Walley T
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.261
Subject(s) - scope (computer science) , clinical pharmacology , health technology , regulatory science , business , pharmacology , medicine , computer science , political science , health care , law , programming language , pathology
Health technology assessment (HTA) is as important as regulation to allow patients access to new medicines, and there are demands that the two processes should be carried out more closely together in time. Although the methods used by the regulator differ from those used by the health technology assessor, there is scope for synergies that would be useful to both parties. By providing scientific advice to sponsors of new medicines, both regulators and health technology assessors can also provide support for drug innovation. Clinical Pharmacology & Therapeutics (2010) 87 2, 152–154. doi: 10.1038/clpt.2009.261